Q-omics provides the consensus-scored LNCSRLR profile across patient tissues and cancer cell-line models. LNCSRLR expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, LNCSRLR is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, LNCSRLR RNA expression shows 14,726 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight CESC, KIRC, and KIRP as cancer lineages where LNCSRLR shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LNCSRLR — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LNCSRLR survival associations across molecular data types. LNCSRLR RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LNCSRLR RNA expression–survival associations across cancer types. High LNCSRLR expression shows unfavorable associations in CESC, LIHC, COAD, KICH, HNSC and LGG. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for LNCSRLR RNA expression.
This table summarizes LNCSRLR tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LNCSRLR. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LNCSRLR shows higher tumor expression in KIRC, HNSC, KIRP, LIHC, LUAD and LUSC. The KIRC box plot shows higher LNCSRLR RNA expression in tumor versus normal tissue (log2 FC = +1.823, t-test p < 0.001).
This table shows molecular features associated with LNCSRLR in patient tissues and cancer cell lines. In patient samples, LNCSRLR shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
